SCHEMBL798325

SCHEMBL798325

CCCC[CH]NC(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1556426 0.93 EP300 (0.42)
SCHEMBL10886696 0.91 EP300 (0.45)
SCHEMBL10893304 0.91 EP300 (0.45)
SCHEMBL10531391 0.91 EP300 (0.45)
SCHEMBL998029 0.85
SCHEMBL204638 0.79 TSHR (0.41)
SCHEMBL1557183 0.79 MEN1 (0.39)
SCHEMBL798306 0.79 CNR1 (0.33)
SCHEMBL8006098 0.79
SCHEMBL8041648 0.79 TSHR (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330678-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 US claimed
EP-3846808-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-07-14 EP claimed
US-9949966-B2 Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMAN-LA ROCHE INC. (US) 2018-04-24 US claimed
EP-3099685-B1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2018-04-18 EP claimed
EP-3099685-A1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-12-07 EP claimed
US-20160296515-A1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2016-10-13 US claimed
US-9458153-B2 Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US claimed
US-20160207914-A9 Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2016-07-21 US claimed
WO-2015113990-A1 NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 WO claimed
US-20150210682-A1 Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2015-07-30 US claimed
EP-2616079-A1 TREATMENT OF BACTERIAL INFECTIOUS DISEASES University of Zürich (CH) 2013-07-24 EP claimed
WO-2012034955-A1 TREATMENT OF BACTERIAL INFECTIOUS DISEASES UNIVERSITY OF ZURICH (CH) 2012-03-22 WO claimed
EP-4219767-A1 PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION F. Hoffmann-La Roche AG (CH) 2023-08-02 EP disclosed
CN-116196411-A PAPD5 and PAPD7 inhibitors for the treatment of hepatitis B infection 豪夫迈·罗氏有限公司 2023-06-02 CN disclosed
CN-109328237-B Inhibitors of PAPD5 and PAPD7 for the treatment of hepatitis b infection 豪夫迈·罗氏有限公司 2022-12-06 CN disclosed
US-20220096527-A1 PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION HOFFMANN-LA ROCHE INC. (US) 2022-03-31 US disclosed
WO-1998028313-A1 (THIO)MORPHOLINE-SUBSTITUTED CARBOXYLIC AND PHOSPHINIC ACIDS NOVARTIS AG (CH) 1998-07-02 WO disclosed
WO-1997009335-A1 SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 1997-03-13 WO disclosed
US-4918074-A CALCIUM ANTAGONISTS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-04-17 US disclosed
EP-0217142-A2 A polyazaheterocyclic compound Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1987-04-08 EP disclosed